Prometheus Biosciences Valuation
Based on Macroaxis valuation methodology, the company cannot be evaluated at this time. Prometheus Biosciences recent Real Value cannot be determined due to lack of data. The prevailing price of Prometheus Biosciences is $0.0. Our model determines the value of Prometheus Biosciences from analyzing the company fundamentals such as Shares Owned By Insiders of 16.61 %, return on equity of -0.33, and Current Valuation of 4.39 B as well as examining its technical indicators and probability of bankruptcy.
Prometheus Biosciences Total Value Analysis
Prometheus Biosciences is at this time forecasted to have valuation of 4.39 B with market capitalization of 9.56 B, debt of 14.76 M, and cash on hands of 95.96 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Prometheus Biosciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.39 B | 9.56 B | 14.76 M | 95.96 M |
Prometheus Biosciences Investor Information
About 17.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 3.54. Prometheus Biosciences had not issued any dividends in recent years. The entity had 1:100 split on the 1st of November 2013. Based on the key indicators related to Prometheus Biosciences' liquidity, profitability, solvency, and operating efficiency, Prometheus Biosciences is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Prometheus Biosciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Prometheus Biosciences has an asset utilization ratio of 0.92 percent. This suggests that the Company is making $0.009192 for each dollar of assets. An increasing asset utilization means that Prometheus Biosciences is more efficient with each dollar of assets it utilizes for everyday operations.Prometheus Biosciences Ownership Allocation
Prometheus Biosciences owns a total of 47.81 Million outstanding shares. The majority of Prometheus Biosciences outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Prometheus Biosciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Prometheus Biosciences. Please pay attention to any change in the institutional holdings of Prometheus Biosciences as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Prometheus Biosciences Profitability Analysis
The company reported the previous year's revenue of 6.81 M. Net Loss for the year was (141.75 M) with loss before overhead, payroll, taxes, and interest of (106.04 M).Prometheus Biosciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 40.6 M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Prometheus Stock
If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |